Answers are grounded in this paper and cite their sources.
These preclinical data support the clinical evaluation of ADI-001, an allogeneic CD20 CAR⁺ Vδ1 γδ T cell, and a phase 1 study has been initiated in patients with B-cell malignancies (NCT04735471).
No takes yet. Share an insight, caveat, or question.
Nishimoto et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: